Studio clinico NCT05949606 · Non-small Cell Lung Cancer

Studio clinico NCT05949606 (fase I/II) risulta «attivo (non in reclutamento)» su ClinicalTrials.gov.

Patologia: Non-small Cell Lung Cancer · Interventi registrati: SI-B001, SI-B003 · Date registrate (fonte): 2023-10-30, 2026-12, 2023-07-18, 2026-08-28.

Sintesi dello studio (fonte: ClinicalTrials.gov, testo originale in inglese):

Phase Ib: To observe the safety and tolerability of the combination of SI-B001 and SI-B003, and to determine the recommended dose of phase II clinical study (RP2D) in the indication of locally advanced or metastatic non-small cell lung cancer. Phase II: To evaluate the efficacy of SI-B001+SI-B003 combination with or without chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer.

Fonte: https://clinicaltrials.gov/study/NCT05949606